Timothy B. Donaldson serves as the head of the firm’s Bio/Pharmaceutical Practice Group. Mr. Donaldson provides legal counseling and services relating to the procurement and enforcement of intellectual property rights, focusing his practice in the biotechnological, pharmaceutical, and chemical arts. Mr. Donaldson has more than twenty years of experience in all aspects of patent law, including drafting and prosecuting patent applications; preparing opinions of counsel addressing patentability, infringement, enforceability, and inventorship; advising clients in developing worldwide patent portfolio and prosecution strategies; diligence, litigation; and licensing. He has particular expertise in the areas of pharmaceuticals, modified-release formulations, small molecules, monoclonal antibodies and related binding proteins, including antibody-drug-conjugates, RNA interference, lipid-based nanoparticles, vaccines, chimeric antigen receptors, CRISPR, DNA and protein molecules, diagnostic and therapeutic methods, including oncoimmunology, DNA expression vectors, microbiology, fermentation and cell culture methods, transgenic plants, yeast expression systems, drug screening, cosmetics, and food products.
Before joining MH2 Technology Law Group, LLP, Mr. Donaldson was a partner at Latimer Intellectual Property Law, LLP, and prior to that an attorney with Finnegan, Henderson, Farabow, Garrett & Dunner, for seven years.
Mr. Donaldson’s scientific background includes work in cellular and molecular immunology, parasitology, and viral-based gene expression in plants. He obtained a B.S. and M.S. in Biology from Wake Forest University and completed some doctoral work at Yale University before embarking on his legal career.